Phase
Condition
Pain
Chronic Pain
Opioid Use Disorder
Treatment
Probenecid
Clinical Study ID
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Adults with chronic pain. Age greater than or equal to 18 years on the day ofenrolment.
Subjects are currently taking a daily opioid pain medication and planning to taperthe dose.
Participants complete at least one voluntary opioid dose reduction in thetwelve-week study period.
Glomerular filtration rate (GFR) > 50 mL/min
Capable of providing informed consent
Exclusion
Exclusion Criteria:
Allergy to probenecid or related drugs
History of uric acid renal calculi, if known to be urate calculi. If unknown type,then any history of renal calculi.
Known G6PD deficiency
Active gout in any joint
Current use of drugs whose exposure may be prolonged, or risk of toxicity increasedwhen used in combination with probenecid:
Penicillins, specifically ampicillin, penicillin G sodium, and piperacillin
Carbapenems, specifically doripenem and meropenem
Lorazepam, midazolam, nitrazepam
Ketorolac
Oseltamivir
Methotrexate
Mycophenolate
Current use of drugs which may mask symptoms of withdrawal: a. Clonidine, lofexidine, tizanidine
Current use of drugs which may diminish the effect of probenecid: a. High dose salicylates including greater than 325 mg PO daily of acetylsalicylicacid (ASA)
Pregnancy or breastfeeding
Any major comorbid medical condition which might impair follow-up or result in asafety risk to the participant
Participation in another clinical trial investigating a drug, medical device, or amedical procedure during the 30 days prior to enrolment.
Study Design
Study Description
Connect with a study center
Richmond Road Diagnostic and Treatment Centre
Calgary, Alberta T2T 5C7
CanadaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.